Cumming School of Medicine, Department of Pathology & Laboratory Medicine, the University of Calgary, Alberta, Canada; Cumming School of Medicine, Department of Microbiology, Immunology, and Infectious Diseases, the University of Calgary, Canada; Calvin, Phoebe & Joan Snyder Institute for Chronic Diseases, the University of Calgary, Calgary, Alberta, Canada.
Cumming School of Medicine, Department of Pathology & Laboratory Medicine, the University of Calgary, Alberta, Canada; Cumming School of Medicine, Department of Microbiology, Immunology, and Infectious Diseases, the University of Calgary, Canada; Calvin, Phoebe & Joan Snyder Institute for Chronic Diseases, the University of Calgary, Calgary, Alberta, Canada; Alberta Precision Laboratories, Diagnostic & Scientific Centre, Calgary, Alberta, Canada.
Diagn Microbiol Infect Dis. 2022 Mar;102(3):115606. doi: 10.1016/j.diagmicrobio.2021.115606. Epub 2021 Nov 23.
The SARS-CoV-2 coronavirus pandemic has been an unprecedented challenge to global pandemic response and preparedness. With the continuous appearance of new SARS-CoV-2 variants, it is imperative to implement tools for genomic surveillance and diagnosis in order to decrease viral transmission and prevalence. The ADSSpike workflow was developed with the goal of identifying signature SNPs from the S gene associated with SARS-CoV-2 variants through amplicon deep sequencing. Seventy-two samples were sequenced, and 30 mutations were identified. Among those, signature SNPs were linked to 2 Zeta-VOI (P.2) samples and one to the Alpha-VOC (B.1.17). An average depth of 700 reads was found to properlycorrectly identify all SNPs and deletions pertinent to SARS-CoV-2 mutants. ADSSpike is the first workflow to provide a practical, cost-effective, and scalable solution to diagnose SARS-CoV-2 VOC/VOI in the clinical laboratory, adding a valuable tool to public health measures to fight the COVID-19 pandemic for approximately $41.85 USD/reaction.
SARS-CoV-2 冠状病毒大流行对全球大流行应对和防范是一个前所未有的挑战。随着新的 SARS-CoV-2 变体的不断出现,必须实施基因组监测和诊断工具,以降低病毒传播和流行率。ADSSpike 工作流程的开发目标是通过扩增子深度测序,从与 SARS-CoV-2 变体相关的 S 基因中识别出特征性单核苷酸多态性(SNP)。对 72 个样本进行了测序,共发现 30 个突变。其中,特征性 SNP 与 2 个 Zeta-VOI(P.2)样本和 1 个 Alpha-VOC(B.1.17)样本有关。发现平均深度为 700 个读数可以正确识别与 SARS-CoV-2 突变体相关的所有 SNP 和缺失。ADSSpike 是第一个为临床实验室诊断 SARS-CoV-2 VOC/VOI 提供实用、经济高效且可扩展解决方案的工作流程,为抗击 COVID-19 大流行的公共卫生措施增加了一个有价值的工具,每个反应的成本约为 41.85 美元。